Target intelligence / Profile preview

Ornithine decarboxylase antizyme 2 (OAZ2)

Target
OAZ2
Molecular classification
Regulatory protein, Polyamine regulatory protein, Other
01

Overview

Ornithine decarboxylase antizyme 2 (OAZ2) is a regulatory protein encoded by the OAZ2 gene in humans. It belongs to the ornithine decarboxylase antizyme family, whose primary function is to negatively regulate ornithine decarboxylase (ODC) activity—the enzyme catalyzing the first and rate-limiting step in polyamine biosynthesis. Antizyme 2 binds to ODC, inhibiting its enzymatic activity and thus reducing intracellular polyamine levels[2][3]. Unlike antizyme 1 (OAZ1), OAZ2 does not accelerate ODC degradation but acts as a direct inhibitor. OAZ2 therefore helps maintain cellular polyamine homeostasis, with relevance to processes such as cell growth, proliferation, and differentiation. Dysregulation of this pathway—especially ODC overactivity—is linked to pathological conditions, including several cancers, due to the fundamental role of polyamines in cell cycle progression and survival[1][2][3].

Other names
OAZ2Ornithine decarboxylase antizyme IIAntizyme 2
02

Mechanism of action

not applicable (no drugs directly target OAZ2; mechanistic relevance is regulatory inhibition of ODC enzyme activity[2][3])

03

Biological functions

Negative regulation of ornithine decarboxylase (ODC) activityRegulation of polyamine biosynthesisRegulation of intracellular polyamine uptake
04

Disease associations

Cancer (indirectly, through regulation of polyamine metabolism)Cell proliferation (regulation of processes linked to cell growth)Other (general control of metabolic homeostasis)
05

Safety considerations

none specific to OAZ2 as a therapeutic target, since it is not a direct drug target; aberrant regulation of polyamines is associated with disease, but no safety concerns specific to manipulating OAZ2 are noted in current literature
06

Interacting drugs

none specifically known; no direct drug-targeting agents listed for OAZ2 as of current knowledge (OAZ2 is not a common direct drug target)
07

Biomarkers

none established specifically for OAZ2 in clinical use; ODC/antizyme system alterations may serve as broader biomarkers in research, especially in cancer

Beyond the preview

Go deeper on Ornithine decarboxylase antizyme 2 (OAZ2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ornithine decarboxylase antizyme 2 (OAZ2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call